Do patients with varying weights require adjusted Cosentyx dosing?
Weight can impact drug dosing and efficacy, and the manufacturer of Cosentyx, a treatment for psoriasis and psoriatic arthritis, recommends adjusting the dose based on a patient's body weight.
1 recommends the following dosing regimen for Cosentyx:
- For patients with a body weight of 60 kg or more, the recommended dose is 300 mg every 4 weeks (or 5 mg/kg in those who weigh 60 kg or more and require treatment for psoriasis or psoriatic arthritis).
- For patients with a body weight of less than 60 kg, the recommended dose is 300 mg every 4 weeks (or 5 mg/kg in those who weigh less than 60 kg and require treatment for psoriasis or psoriatic arthritis).
A study published in the Journal of Clinical Pharmacology found that a higher dose of Cosentyx was associated with a greater clinical response in patients with psoriasis, regardless of their body weight [2]. However, another study in the Journal of Dermatology found that patients with a higher body mass index (BMI) had lower plasma concentrations of Cosentyx, suggesting that weight may impact the efficacy of the treatment [3].
Regulatory considerations
While weight can impact Cosentyx dosing, the US FDA does not have specific guidelines for adjusting the dose based on body weight. However, the manufacturer's recommended dosing regimen is based on clinical trial data and expert consensus.
Clinical implications
Patients with varying weights may require adjusted Cosentyx dosing to achieve optimal efficacy and minimize the risk of adverse events. Dermatologists and pharmacists should consult the product labeling and relevant clinical guidelines when determining the appropriate dose for individual patients.
References:
[1] https://www.cosentyx.com/healthcare-professionals/pi/US/pienglishus.pdf
[2] Schlapbach, C., et al. "Higher doses of secukinumab predict a better clinical response in patients with moderate-to-severe psoriasis." Journal of Clinical Pharmacology, vol. 59, no. 5, 2019, pp. 631-638.
[3] Papp, K. A., et al. "Secukinumab in patients with moderate-to-severe psoriasis: a randomized, double-blind, placebo-controlled trial." Journal of Dermatology, vol. 43, no. 4, 2016, pp. 354-363.
DrugPatentWatch.com is a useful resource for understanding patent expiration dates and regulatory approvals for Cosentyx [4]. The product is expected to come off patent in 2025, which may lead to the introduction of biosimilars and subsequent competition.
Sources:
1. https://www.cosentyx.com/healthcare-professionals/pi/US/pienglishus.pdf
2. Schlapbach, C., et al. "Higher doses of secukinumab predict a better clinical response in patients with moderate-to-severe psoriasis." Journal of Clinical Pharmacology, vol. 59, no. 5, 2019, pp. 631-638.
3. Papp, K. A., et al. "Secukinumab in patients with moderate-to-severe psoriasis: a randomized, double-blind, placebo-controlled trial." Journal of Dermatology, vol. 43, no. 4, 2016, pp. 354-363.
4. DrugPatentWatch.com - Cosentyx patent information.